|
The Board of Henderson Morley announces that further to the Chairman’s statement which accompanied the results for the full year, the initial phase of the field studies has now been completed.
The vaccine candidates under examination were formulated to give a wide range of doses, using proprietary adjuvants (compounds that help boost and increase the duration of immune responses). The results from the study have demonstrated that the vaccine candidates were safe and well tolerated, with adverse effects no greater than unvaccinated controls.
Fish were vaccinated and examined, amongst other parameters, for immune responses to vaccination, vaccination dose, vaccination safety and assessment of the safety and immunogenicity of the new adjuvant. The studies have given a much greater understanding of immune responses and dose requirements. It is likely that from the next phase of studies, due to start in Jan 2009, a final vaccine candidate will be selected.
Commenting on the announcement, Andrew Knight, Henderson Morley Executive Chairman said: “This is an important first stage in studying the efficacy of the KHV vaccine. We can now move forwards to the next phase of the study which we anticipate will start in early January 2009.”
|
